Literature DB >> 2901865

CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects.

K L Davis1, M Davidson, R K Yang, B M Davis, L J Siever, R C Mohs, T Ryan, E Coccaro, L Bierer, S D Targum.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901865     DOI: 10.1016/0006-3223(88)90147-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  5 in total

Review 1.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

2.  Potential Use of Exfoliated and Cultured Olfactory Neuronal Precursors for In Vivo Alzheimer's Disease Diagnosis: A Pilot Study.

Authors:  Agustín Riquelme; Marcela Valdés-Tovar; Oscar Ugalde; Vanessa Maya-Ampudia; Monserrat Fernández; Leticia Mendoza-Durán; Leslye Rodríguez-Cárdenas; Gloria Benítez-King
Journal:  Cell Mol Neurobiol       Date:  2019-08-14       Impact factor: 5.046

3.  Somatostatin cerebrospinal fluid levels in dementia.

Authors:  A Molins; R Catalán; J Sahuquillo; J M Castellanos; A Codina; R Galard
Journal:  J Neurol       Date:  1991-06       Impact factor: 4.849

4.  Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate-induced neurotoxicity.

Authors:  Ujendra Kumar
Journal:  J Mol Neurosci       Date:  2008-05-16       Impact factor: 3.444

5.  Somatostatin Ameliorates β-Amyloid-Induced Cytotoxicity via the Regulation of CRMP2 Phosphorylation and Calcium Homeostasis in SH-SY5Y Cells.

Authors:  Seungil Paik; Rishi K Somvanshi; Helen A Oliveira; Shenglong Zou; Ujendra Kumar
Journal:  Biomedicines       Date:  2021-01-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.